CLASS ACTION NOTICE: Berger Montague Advises Elanco Animal Health (NYSE: ELAN) Investors to Inquire About a Securities Fraud Class Action

Core Viewpoint - A lawsuit has been filed against Elanco Animal Health on behalf of investors who purchased its securities between November 7, 2023, and June 26, 2024, due to significant stock price decline following FDA approval updates [1][5]. Company Overview - Elanco Animal Health develops products for pets and farm animals, including Zenrelia, an oral Janus kinase inhibitor for canine dermatology, and Credelio Quattro, a parasiticide for dogs [2]. FDA Approval Timeline - In November 2023, Elanco set a timeline for U.S. FDA approval of Zenrelia and Credelio Quattro in the first half of 2024 [3]. - By May 2024, Elanco updated its timeline, expecting Zenrelia's approval and commercial launch in Q3 2024, and Credelio Quattro's approval in Q3 2024 with a launch in Q4 2024 [3]. - On June 27, 2024, Elanco indicated that Zenrelia would include a boxed safety warning, potentially slowing product adoption by approximately 25%, with expected FDA approval in Q3 2024 and a commercial launch in Q4 2024 for both products [4]. Stock Price Impact - Following the announcement regarding the FDA approval timelines and safety warnings, Elanco's stock price fell by $3.69 per share, or 20%, closing at $14.28 per share on June 27, 2024 [5].